IBM Watson Health and EBSCO Information Services are combining their clinical decision support platforms – DynaMed and IBM Micromedex – into a single solution called DynaMed and Micromedex with Watson. The companies said the combined solution is designed to bring together drug and disease content into a single search for evidence-based insights to help inform clinical decisions.
DynaMed and Micromedex with Watson is designed to use artificial intelligence and natural language processing to bypass keyword searches in favor of a more conversational approach to search.
DynaMed provides peer-reviewed clinical content including systematic literature reviews in 28 specialties for comprehensive disease topics, health conditions, and abnormal findings to highly focused topics on evaluation, differential diagnosis, and management. IBM Micromedex is one of the largest online reference databases for medication information. It is used by more than 4,500 hospitals and health systems worldwide for decision-making in medication therapy management, disease and condition management, toxicology, alternative medicine and patient education.
“Research shows that healthcare provider confidence in clinical decision support recommendations comes from knowing the evidence-based methodologies that helped build the content foundation,” said Anil Jain, vice president and chief health information officer of IBM Watson Health, in a statement.
DynaMed and Micromedex with Watson is expected to be available for general adoption in spring, 2020. IBM and EBSCO will also continue to sell the IBM Micromedex and DynaMed solutions separately.